ZEOX 8-K/A
Zeo ScientifiX, Inc. (ZEOX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Amendment No. 1 to Form 8-K
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Form 8-K/A (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.
EXPLANATORY NOTE
| Item 7.01 | Regulation FD Disclosure. |
On November 15, 2024, Robin L. Smith, M.D., M.B.A., a co-founder of Exotropin, LLC (“Exotropin”), will be conducting a presentation entitled “Exosomes are the new Frontier in Aesthetics: Not All Exosomes are Alike” at the Medical Aesthetics Professionals (“MAP”) meeting being held in Scottsdale, Arizona., Exotropin is a privately-held developer of advanced cosmeceuticals using exosomes and other proprietary technology. ZEO holds a minority equity interest in Exotropin and is collaborating with Exotropin on the development of various products, including, ZEO HAIR GROW™ Powered By Exotropin™, which is being introduced at the MAP meeting and which is featured in the presentation.
A copy of the PowerPoint slides pertaining to the ZEO HAIR GROW™ Powered By Exotropin™ to be used in connection with Dr. Smith’s presentation is attached as Exhibit 99.1 to this Report.
The foregoing information, including the PowerPoint presentation attached as Exhibit 99.1 to this Report, is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |
| 99.1* | November 15, 2024 PowerPoint Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Furnished but not filed. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 22, 2024 | ZEO SCIENTIFIX, INC. | |
| By: | /s/ Ian T. Bothwell | |
| Ian T. Bothwell | ||
| Interim Chief Executive Officer and Chief Financial Officer | ||
2
Exhibit 99.1
Private and Confidential. © 2024 ZEO ScientifiX , Inc. All rights reserved.
• G lobal business leader, medical doctor, author, speaker and entrepreneur in the healthcare industry. • T railblazer in regenerative medicine and predictive analytics and has focused on turnarounds, M&A and disruptive innovations in m edicine. • R eceived B.A. from Yale University, M.D. from the Yale School of Medicine, M.B.A. from the Wharton School of Business, the Stanford University Directors Program and received an honorary Doctor of Science degree from TJMC. • Founded Spiritus Therapeutics, Exotropin , LLC and Neostem , the Cura Foundation and BRM Holdings . • S erved as a member of the executive board of trustees of Sanford Health, Sanford Health’s International Board and the board of trustees of the New York University Langone Medical Center as well as chairman of the board of directors of the New York University Hospital for Joint Diseases . Robin L. Smith, M.D., MBA
Exosomes provide signal to: • Repair • Restore • Rejuvenate • Replenish NEW FRONTIER IN BEAUTY AND ANTI - AGING Exosomes carry proteins, peptides, lipids and nucleic acids that play a vital role in renewing and rejuvenating the appearance of skin and hair. When applied topically, through intercellular communication , exosomes deliver their cargo to assist with a vast array of functions to enhance the overall condition of the scalp and hair. • Reduce environmental stress • Redensify • Renew • Regenerate
THE GROWING HAIR LOSS INDUSTRY $3.5 Billion spent on all hair loss treatments “ 99% of all products Being marketing are completely ineffective” Washington Post Hair Restoration Patients 358,109 surgical patients 697,372 non - surgical patients $2.5 Billion spent on surgical procedures How many people in the U.S. are experiencing hair loss? 35 mil Men 31 mil Women 2020 Practice Census Results – International Society of Hair Restoration Surgery
HAIR LOSS IS MULTIFACTORIAL Phases of Hair Growth Catagen Telogen Return Anagen Anagen THE APPROACH TO REVITALIZE THE CONDITION AND APPPEARANCE OF HAIR MUST BE AS WELL
A 90 - DAY PHYSICIAN FORMULATED HAIR GROW SYSTEM A UNIQUE FIRST - OF - ITS - KIND SYSTEM A Multifactorial Approach Combin ing the Synergistic & Complimentary Power of • Amniotic Fluid Extract Exosomes (GROWX) • Adipose Derived Exosomes (eXo 3 ) • Aloe Vera Exosomes (aloe 3 ) To Replenish and Optimize the Condition of the Scalp and Promote the Appearance of Thicker, Fuller Looking Hair
THE POTENT COMBINATION BEHIND THE ZEO HAIR GROW SYSTEM aloe 3 (Aloe) Exosomes eXo 3 (ASC) Exosomes ZEO HAIR GROW includes the potent combination of three different sources of exosomes and added signaling molecules formulated together into a system designed to renew and replenish, making your hair look fuller, stronger and thicker. Each exosome source has its own unique signature , creating an unmatched solution for restoring the vitality of the scalp and improving the hair’s condition and appearance. Amniotic Fluid (AF) or PPX Autologous Exosomes
COMPLEMENTARY & SYNERGISTIC SECRETOMES ZEO GROW X + ZEO GROW BOOST Amniotic Fluid Extract + Potent Growth Factor Booster In O ffice “Induction/Stimulation” Procedure EXO FOLLICLE FUEL eXo 3 Exosomes + a l oe 3 E xosomes Hair & Scalp Spray At Home Maintenance P rotocol Delivers necessary support for scalp health until next GROWX + GROW BOOST In Office procedure • F ormulated to support and maintain the environment of the scalp to promote healthy hair, and natural growth. • Provides essential nutrients to completely nourish and hydrate the scalp and hair. • Targeted formulations to protect the scalp and reduce factors causing environmental and mechanical stressors to the scalp and hair follicles in order to thicken and redensify hair. • Deliver ing the necessary and relevant fortifying resources to replenish, strengthen and optimize the condition and appearance of the hair and scalp. The Sequential Combined Approach
WE INVITE YOU TO VISIT US AT BOOTH #609